Ssgj-612
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Locally Advanced (Unresectable) or Metastatic Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ssgj-705 Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | CCC |
txn10128 Txinno Bioscience Inc. | Phase 1 | CC |
Irinotecan Txinno Bioscience Inc. | Phase 1 | CC |
Neok001 NEOK Bio, Inc. | Phase 1 | CC |
Neok002 NEOK Bio, Inc. | Phase 1 | CC |
Same molecule, other indications
Ssgj-612 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →